Planning the hepatitis C virus elimination in Cyprus: A modeling study

被引:1
|
作者
Gountas, Ilias [1 ]
Yiasemi, Ioanna [2 ]
Kyprianou, Evi [2 ]
Mina, Christos [2 ]
Georgiou, Chrysanthos [3 ]
Katsioloudes, Petros [4 ]
Kouroufexi, Andri [5 ]
Demetriou, Anna [6 ]
Xenofontos, Elena [7 ]
Nikolopoulos, Georgios [1 ]
机构
[1] Univ Cyprus, Med Sch, Cyprus Hgkoyntas Meduoagr, Kalipoleos 75, CY-1678 Nicosia, Cyprus
[2] Cyprus Natl Addict Author, Cyprus Monitoring Ctr, CY-1678 Nicosia, Cyprus
[3] Nicosia Gen Hosp, CY-1678 Nicosia, Cyprus
[4] Evangelistria Med Ctr, CY-1678 Nicosia, Cyprus
[5] Minist Hlth, Pharmaceut Serv, CY-1678 Nicosia, Cyprus
[6] Minist Hlth, Hlth Monitoring Unit, CY-1678 Nicosia, Cyprus
[7] Limassol Gen Hosp, Dept Internal Med, CY-4131 Limassol, Cyprus
关键词
Mathematical modelling; Projections; Hepatitis C virus elimination; Direct-acting antivirals; Screening campaigns; INJECT DRUGS; HCV; PEOPLE; INFECTION; REINFECTION; SOFOSBUVIR;
D O I
10.3748/wjg.v27.i31.5219
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Hepatitis C virus (HCV) infection is a major global public health problem. In the Republic of Cyprus, the estimated prevalence of chronic hepatitis C (CHC) among the general population is 0.6%, while the CHC prevalence among people who inject drugs (PWID) is estimated at 46%. Direct-acting antivirals that can eliminate HCV are not yet widely available in the Republic of Cyprus. However, when direct-acting antivirals become available, a long-term strategic plan to guide elimination efforts will be needed to maximize the effect of treatment. AIM To determine the programmatic targets to eliminate HCV in the Republic of Cyprus. METHODS A dynamic, stochastic, individual-based model of HCV transmission, disease progression, and cascade of care was calibrated to data from Cyprus. The model stratifies the population into the infected general population and the PWID population. A variety of test, prevention, and treatment strategies concerning the general population, PWID, or both were examined. The time horizon of the analysis was until 2034. RESULTS Under the status quo scenario, the model predicted that 75 (95% confidence interval (CI): 60, 91) and 575 (95%CI: 535, 615) liver-related deaths and new infections would occur by 2034, respectively. Launching an expanded treatment program, without screening interventions, would cause modest outcomes regarding CHC prevalence (16.6% reduction in 2034 compared to 2020) and liver-related deaths (10 deaths would be prevented compared to the status quo scenario by 2034). Implementing a test and treat strategy among the general population but without any intervention in the PWID population would suffice to meet the mortality target but not the incidence target. To achieve HCV elimination in Cyprus, 3080 (95%CI: 3000, 3200) HCV patients need to be diagnosed and treated by 2034 (2680 from the general population and 400 from PWID), and harm reduction coverage among PWID should be increased by 3% per year (from 25% in 2020 to 67% in 2034). CONCLUSION Elimination of HCV is a demanding public health strategy, which requires significant interventions both among the general population and high-risk groups.
引用
收藏
页码:5219 / 5231
页数:13
相关论文
共 50 条
  • [21] Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
    Wu, Meiyu
    Ma, Jing
    Li, Sini
    Qin, Shuxia
    Tan, Chongqing
    Xie, Ouyang
    Li, Andong
    Lim, Aaron G.
    Wan, Xiaomin
    PHARMACOECONOMICS, 2024, 42 (12) : 1345 - 1357
  • [22] Seroprevelance of Hepatitis B Virus, Hepatitis C Virus and Human Immunodeficiency Virus in Northern Cyprus
    Guler, Emrah
    Suer, Kaya
    Arikan, Ayse
    Guvenir, Meryem
    Sanlidag, Tamer
    MEDICAL JOURNAL OF BAKIRKOY, 2018, 14 (04) : 332 - 338
  • [23] Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide
    Tai, Chi-Ming
    Yu, Ming-Lung
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2024, 40 (02) : 112 - 118
  • [24] The Second Canadian Symposium on Hepatitis C Virus: A call to action
    Grebely, Jason
    Bilodeau, Marc
    Feld, Jordan J.
    Bruneau, Julie
    Fischer, Benedikt
    Raven, Jennifer F.
    Roberts, Eve
    Choucha, Norma
    Myers, Rob P.
    Sagan, Selena M.
    Wilson, Joyce A.
    Bialystok, Frank
    Tyrrell, D. Lorne
    Houghton, Michael
    Krajden, Mel
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 27 (11) : 627 - 632
  • [25] Hepatocellular organellar abnormalities following elimination of hepatitis C virus
    Aoyagi, Haruyo
    Iijima, Hiroko
    Gaber, Eman S.
    Zaitsu, Takuma
    Matsuda, Mami
    Wakae, Kosho
    Watashi, Koichi
    Suzuki, Ryosuke
    Masaki, Takahiro
    Kahn, Jeffrey
    Saito, Takeshi
    El-Kassas, Mohamed
    Shimada, Noritomo
    Kato, Keizo
    Enomoto, Masaru
    Hayashi, Kazuhiko
    Tsubota, Akihito
    Mimata, Ayako
    Sakamaki, Yuriko
    Ichinose, Shizuko
    Muramatsu, Masamichi
    Wake, Kenjiro
    Wakita, Takaji
    Aizaki, Hideki
    LIVER INTERNATIONAL, 2023, 43 (08) : 1677 - 1690
  • [26] From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy
    Kondili, Loreta A.
    Craxi, Lucia
    Nava, Felice
    Babudieri, Sergio
    D'Ambrosio, Roberta
    Marcellusi, Andrea
    Mennini, Francesco Saverio
    Valle, Sabrina
    Russo, Pierluigi
    Olimpieri, Pier Paolo
    Andreoni, Massimo
    Aghemo, Alessio
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 : S211 - S220
  • [27] Universal Screening for Hepatitis C: An Important Step in Virus Elimination
    Chhatwal, Jagpreet
    Sussman, Norman L.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (05) : 835 - 837
  • [28] Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison
    Ward, Zoe
    Mafirakureva, Nyashadzaishe
    Stone, Jack
    Keevans, Mary
    Betts-Symonds, Graham
    Crowley, Desmond
    McHugh, Tina
    Avramovic, Gordana
    Lambert, John S.
    Vickerman, Peter
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 96
  • [29] Australia needs to increase testing to achieve hepatitis C elimination
    Scott, Nick
    Sacks-Davis, Rachel
    Wade, Amanda J.
    Stoove, Mark
    Pedrana, Alisa
    Doyle, Joseph S.
    Thompson, Alexander J.
    Wilson, David P.
    Hellard, Margaret E.
    MEDICAL JOURNAL OF AUSTRALIA, 2020, 212 (08) : 365 - 370
  • [30] Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany
    Tergast, Tammo L.
    Blach, Sarah
    Tacke, Frank
    Berg, Thomas
    Cornberg, Markus
    Kautz, Achim
    Manns, Michael
    Razavi, Homie
    Sarrazin, Christoph
    Serfert, Yvonne
    van Thiel, Ingo
    Zeuzem, Stefan
    Wedemeyer, Heiner
    JOURNAL OF VIRAL HEPATITIS, 2022, 29 (07) : 536 - 542